Microglial cells are the resident immune cells of the central nervous system (CNS), representing the brain's primary defense mechanism against pathogens, injury, and disease. As the CNS equivalent of peripheral macrophages, microglia arise from embryonic yolk sac progenitors distinct from other myeloid lineages, establishing themselves in the brain early in development and persisting throughout life through self-renewal [1].
In neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), microglia adopt complex activation states that can be both protective and pathogenic. Understanding microglial heterogeneity—through Cell Ontology classifications and disease-associated molecular signatures—is essential for developing targeted therapeutic interventions.
This page provides a navigable hierarchy of microglial cell (CL:0000129) from the Cell Ontology, cross-referenced with NeuroWiki cell type pages.
| Cell Ontology ID | Cell Type | NeuroWiki Page | Word Count |
|---|---|---|---|
| CL:0000129 | microglial cell | Microglia in Alzheimer's Disease | 3200+ |
| CL:0002628 | immature microglial cell | — | — |
| CL:4307132 | microglial cell (Mmus) | — | — |
Coverage: 1/3 types have NeuroWiki pages (33%)
Green nodes link to existing NeuroWiki pages. Blue nodes represent microglial functional states in disease.
Microglia originate from primitive macrophages in the embryonic yolk sac, distinct from bone marrow-derived monocytes that enter the brain only under pathological conditions [1:1]. This embryonic origin establishes microglia as a self-renewing population maintained independently of hematopoietic stem cells throughout life.
Key developmental features:
Under normal conditions, microglia exist in a "surveillance" or "resting" state characterized by:
This surveillance state requires signaling through the colony-stimulating factor 1 receptor (CSF1R), which is essential for microglial survival and maintenance [2].
| Marker | Gene | Function | Disease Relevance |
|---|---|---|---|
| IBA1 | AIF1 | Actin-binding protein | Pan-microglial marker |
| TMEM119 | TMEM119 | Transmembrane protein | Specific to mature microglia |
| P2RY12 | P2RY12 | Purinergic receptor | Homeostatic microglia |
| CX3CR1 | CX3CR1 | Fractalkine receptor | Neuron-microglia communication |
| TREM2 | TREM2 | Triggering receptor | Disease-associated activation |
| CD68 | CD68 | Lysosomal marker | Phagocytic activity |
| CD14 | CD14 | TLR co-receptor | Innate immune response |
Microglia in neurodegenerative diseases upregulate distinct gene modules:
DAM signature (Disease-Associated Microglia):
Neuroinflammation markers:
The traditional M1/M2 classification system, borrowed from peripheral macrophage polarization, has been largely superseded by recognition of diverse microglial activation states [4]:
However, microglial activation in vivo is far more nuanced, with intermediate states reflecting the complex CNS microenvironment.
The landmark study by Keren-Shaul et al. (2017) identified a unique microglia type in Alzheimer's disease models—termed disease-associated microglia (DAM)—characterized by a distinct transcriptional program [5]:
Stage 1 DAM:
Stage 2 DAM:
A contrasting microglial state associated with aging and cognitive decline characterized by:
Microglia in AD exhibit both protective and pathogenic roles [6]:
Protective functions:
Pathogenic functions:
Key genetic risk factors:
Microglial activation in PD contributes to dopaminergic neuron death:
Mechanisms:
Therapeutic targets:
Microglia play complex roles in MS pathogenesis:
| Strategy | Target | Approach | Status |
|---|---|---|---|
| CSF1R inhibition | Proliferation | Small molecule antagonists | Phase 2 trials |
| TREM2 activation | Phagocytosis | Agonistic antibodies | Preclinical |
| Anti-inflammatory | Cytokines | IL-1β, TNF-α blockers | Approved for other diseases |
| Complement inhibition | Synaptic pruning | C1q, C3 inhibitors | Preclinical |
| CX3CR1 modulation | Neuron-microglia signaling | Small molecule modulators | Research |
Colony-stimulating factor 1 receptor (CSF1R) signaling is essential for microglial survival, proliferation, and function. Inhibition via CSF1R antagonists (e.g., PLX3397, PLX5622) leads to microglial depletion and has shown promise in:
However, complete microglial depletion raises concerns about loss of immune surveillance and increased susceptibility to infections.
TREM2 represents one of the most promising microglial targets in neurodegeneration [7:1]:
Rationale:
Therapeutic approaches:
Ginhoux F, Greter M, Leblanc M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010. ↩︎ ↩︎
Elmore MR, Najafi AR, Ikeda Y, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglial viability, priming, and lesion-mediated repair. Nat Neurosci. 2015. ↩︎
Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2016. ↩︎
Ransohoff RM. A polarizing question: do M1 and M2 microglia exist?. Nat Neurosci. 2016. ↩︎
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with Alzheimer's disease. Cell. 2017. ↩︎
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018. ↩︎
Deczkowska A, Amit I, Schwartz M. TREM2 as a therapeutic target. Trends Mol Med. 2018. ↩︎ ↩︎